Amisulpride

Breastfeeding
  • TRADE NAMES: Barhemsys (Acacia Pharma); Deniban (Sanofi-Aventis); Solian (Sanofi-Aventis)
  • INDICATIONS: Prevention of postoperative nausea and vomiting (lower doses). Psychoses, schizophrenia (higher doses)
  • CLASS: Antiemetic, Antipsychotic, Dopamine receptor antagonist
  • HALF-LIFE: 4–5 hours (following intravenous infusion)

FDA APPROVAL DATE: 02/26/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Bepridil, Cisapride, Disopyramide, Droperidol, Erythromycin, Flecainide, Levodopa, Ondansetron, Ondansetron, Pentamidine, Procainamide, Quinidine, Sotalol, Sparfloxacin, Terfenadine, Thioridazine


Insufficient data to establish a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

Approved by FDA for prevention of postoperative nausea and vomiting, February 2020.
Avoid use in patients with congenital long QT syndrome and in patients taking droperidol.

Our database has 56 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top